CSF markers related to pathogenetic mechanisms in Alzheimer's disease

被引：0
|
作者：
C. Mulder
S. N. M. Schoonenboom
L.-O. Wahlund
Ph. Scheltens
G. J. van Kamp
R. Veerhuis
C. E. Hack
M. Blomberg
R. B. H. Schutgens
P. Eikelenboom
机构：
[1] Departments of Clinical Chemistry,
[2] ,undefined
[3]  Neurology,undefined
[4] ,undefined
[5]  Pathology,undefined
[6] and,undefined
[7]  Psychiatry,undefined
[8] Research Institute Neurosciences,undefined
[9] VU University Medical Center,undefined
[10] Amsterdam,undefined
[11] The Netherlands,undefined
[12]  Department of Clinical Neuroscience,undefined
[13] Section of Geriatric Medicine,undefined
[14] Huddinge University Hospital,undefined
[15] Karolinska Institute,undefined
[16] Huddinge,undefined
[17] Sweden,undefined
来源：
Journal of Neural Transmission | 2002年 / 109卷
关键词：
Keywords: C1q; SAP; A-beta (1; 42); tau; pathogenic mechanism.;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Serum amyloid P component (SAP) and complement C1q are found highly co-localized with extracellular fibrillar amyloidβ (Aβ) deposits in Alzheimer's disease (AD) brain. Conflicting data were reported earlier about the cerebrospinal fluid (CSF) levels of SAP and C1q in AD compared to controls. The objective of the present study was to compare the levels of Aβ1–42, tau, C1q and SAP in CSF of a well characterized group of AD patients and controls, and to assess the association with dementia severity.
引用
收藏
页码：1491 / 1498
页数：7
相关论文
共 50 条
  • [1] CSF markers related to pathogenetic mechanisms in Alzheimer's disease
    Mulder, C
    Schoonenboom, SNM
    Wahlund, LO
    Scheltens, P
    van Kamp, GJ
    Veerhuis, R
    Hack, CE
    Blomberg, M
    Schutgens, RBH
    Eikelenboom, P
    JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (12) : 1491 - 1498
  • [2] Biological markers of amyloid β-related mechanisms in Alzheimer's disease
    Hampel, Harald
    Shen, Yong
    Walsh, Dominic M.
    Aisen, Paul
    Shaw, Les M.
    Zetterberg, Henrik
    Trojanowski, John Q.
    Blennow, Kaj
    EXPERIMENTAL NEUROLOGY, 2010, 223 (02) : 334 - 346
  • [3] CSF markers in MCI and Alzheimer's disease
    Blennow, K
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 7 - 8
  • [4] CSF markers for incipient Alzheimer's disease
    Blennow, K
    Hampel, H
    LANCET NEUROLOGY, 2003, 2 (10): : 605 - 613
  • [5] CSF markers for early Alzheimer's disease
    Blennow, K
    Davidsson, P
    Vanmechelen, E
    ALZHEIMER'S DISEASE: ADVANCES IN ETIOLOGY, PATHOGENESIS AND THERAPEUTICS, 2001, : 275 - 283
  • [6] Advances in understanding the pathogenetic mechanisms of Alzheimer's disease
    Govoni, S
    Lanni, C
    Racchi, M
    FUNCTIONAL NEUROLOGY, 2001, 16 (04) : 17 - 30
  • [7] Combination of serum markers related to several mechanisms in Alzheimer's disease
    Teunissen, CE
    Lütjohann, D
    von Bergmann, K
    Verhey, F
    Vreeling, F
    Wauters, A
    Bosmans, E
    Bosman, H
    van Boxtel, MPJ
    Maes, M
    Delanghe, J
    Blom, HJ
    Verbeek, MM
    Rieckmann, P
    De Bruijn, C
    Steinbusch, HWM
    de Vente, J
    NEUROBIOLOGY OF AGING, 2003, 24 (07) : 893 - 902
  • [8] Editorial: CSF clearance in Alzheimer's disease and related dementias: exploring mechanisms and implications
    Li, Yi
    FRONTIERS IN AGING NEUROSCIENCE, 2025, 17
  • [9] Neuropsychological and CSF markers of early and late Alzheimer's disease
    Contardo, C.
    Walker, A.
    Wagner, M.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2008, 23 (06) : 675 - 675
  • [10] The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer's disease
    MeierRuge, W
    BertoniFreddari, C
    REVIEWS IN THE NEUROSCIENCES, 1996, 7 (01) : 1 - 19
12345